NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS
• Poster presentation at the ALS Association’s ALS Nexus conference, August 23-26
• Disclosed that NRG5051 acts by inhibiting the mPTP through a novel NLRX1-mediated mechanism of action
• Data showed that NRG5051 displays profound anti-inflammatory and neuroprotective effects in ALS mouse models